CLASS II Drug recall · Reported 12 Feb 2020 · FDA Enforcement Report

Ranitidine Hydrochloride (powder) recalled

Spectrum Laboratory Products is recalling Ranitidine Hydrochloride (powder), USP, distributed in 11 states. The recall was initiated on 14 Jan 2020 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #:11E0585, Exp. October 2023
Quantity recalledN/A

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0825-2020
FDA event ID
84799
Recalling firm
Spectrum Laboratory Products, Gardena, CA
Classification
Class II
Status
Terminated
Recall initiated
14 Jan 2020
FDA classified
4 Feb 2020
Reported
12 Feb 2020
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity

Timeline

14 Jan 2020Recall initiated by company
4 Feb 2020Classified by FDA+21 days
12 Feb 2020Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: Presence of NDMA impurity detected in product.

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Ranitidine Hydrochloride (powder), USP, Rx only, Spectrum Chemical Mfg Corp., a) 1 gram, b) 5 grams, c) 25 grams, d)100 grams, e) 500 grams, f) 1 Kilogram

Where it was distributed

The recalled API was distributed to pharmacies in the following states: AZ, CA, FL, GA, NJ, PA, RI, SC, TX, UT, WY. The API was also distributed internationally to Canada and UAE.

ArizonaCaliforniaFloridaGeorgiaNew JerseyPennsylvaniaRhode IslandSouth CarolinaTexasUtahWyoming

Questions about this recall

Why was it recalled?

CGMP Deviations: Presence of NDMA impurity detected in product.

Which lots are affected?

Lot #:11E0585, Exp. October 2023

Where was it sold?

The recalled API was distributed to pharmacies in the following states: AZ, CA, FL, GA, NJ, PA, RI, SC, TX, UT, WY. The API was also distributed internationally to Canada and UAE.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Spectrum Laboratory Products

All 9

Other Ranitidine recalls

All 55